Elevation Oncology has become the second biotech this week to face calls from an activist investor to wind down the company.

Evotec’s cost-cutting drive has reached its pipeline. The company axed around 30% of its asset portfolio and offloaded ...

Nine months after Johnson & Johnson stepped back from an Addex Therapeutics-partnered epilepsy drug in the wake of a phase 2 ...

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. | Eli Lilly has met its goal of ...

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

The imaging provider RadNet aims to acquire iCad and its artificial intelligence-powered mammography software—with plans to ...

Like Johnson & Johnson did during its earnings call the day before, Abbott estimated that global tariffs would end up costing ...

Glycomine has bagged a $115 million series C round to continue the progress of its lead candidate through phase 2 development ...

Novartis has terminated a phase 2 trial evaluating an investigational ADAMTS-5 inhibitor for patients with osteoarthritis knee pain. | Novartis has terminated a phase 2 trial evaluating an ...

Essa Pharma is facing a call to wind down operations. Soleus Capital Management, one of the company’s largest shareholders, ...

The Trump administration is freezing more than $2.2 billion in funding to Harvard University after the school defied the ...

When it came to the study’s secondary endpoints of survival, Telix pointed to a median overall survival (OS) rate of 12.4 ...